Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Beta Bionics, Inc.BBNX · Entity 2350 | Director | May 21, 2026 | May 26, 2026 |
| DELCATH SYSTEMS, INC.DCTH · Entity 5387 | Director · CHIEF EXECUTIVE OFFICER | March 02, 2026 | March 03, 2026 |
| Vericel CorpVCEL · Entity 4481 | CFO and VP, Corp. Development | April 01, 2020 | April 03, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Beta Bionics, Inc.
Report date May 21, 2026 · Filed May 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 33,509 |
Reported balance
After 2026-05-21 transaction · row 1
1 source rowRow 1 · 2026-05-21 · Grant · Acquired 16,965 · Balance 33,509 F1: Represents restricted stock unit award granted under the Issuer's 2025 Equity Incentive Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock unit award granted under the Issuer's 2025 Equity Incentive Plan.
DELCATH SYSTEMS, INC.
Report date March 02, 2026 · Filed March 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 342,034 |
Reported balance
After 2026-03-02 transaction · row 1
1 source rowRow 1 · 2026-03-02 · Purchase · Acquired 11,200 · Balance 342,034 |
Vericel Corp
Report date April 01, 2020 · Filed April 03, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 253,865 |
Last balance in matching sequence
After 2020-04-01 transaction · row 7
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
7 source rowsRow 1 · 2020-04-01 · Exercise / conversion · Acquired 10,000 · Balance 172,708 F1: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Row 2 · 2020-04-01 · Exercise / conversion · Acquired 58,519 · Balance 231,227 F1: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Row 3 · 2020-04-01 · Exercise / conversion · Acquired 4,375 · Balance 235,602 F1: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Row 4 · 2020-04-01 · Exercise / conversion · Acquired 3,090 · Balance 238,692 F1: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Row 5 · 2020-04-01 · Exercise / conversion · Acquired 1,875 · Balance 240,567 F1: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Row 6 · 2020-04-01 · Exercise / conversion · Acquired 7,673 · Balance 248,240 F1: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Row 7 · 2020-04-01 · Exercise / conversion · Acquired 5,625 · Balance 253,865 F1: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.95 · Expires 2026-02-09 | Direct | 0 |
Reported balance
After 2020-04-01 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2020-04-01 · Exercise / conversion · Disposed 10,000 · Balance 0 F2: These options, representing the right to purchase a total of 80,000 shares, became exercisable in equal quarterly installments, contingent upon continued service to the Company, with the first vesting date on May 9, 2016, which was one quarter after the date on which the option was granted. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.75 · Expires 2027-02-08 | Direct | 25,173 |
Reported balance
After 2020-04-01 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2020-04-01 · Exercise / conversion · Disposed 4,375 · Balance 25,173 F3: These options, representing the right to purchase a total of 70,000 shares, became exercisable in equal quarterly installments, contingent upon continued service to the Company, with the first vesting date on May 8, 2017, which was one quarter after the date on which the option was granted. F4: These transactions relate to the 70,000 stock options granted to Mr. Michel on February 8, 2017. The remaining beneficially owned stock option (right to buy) after both transactions is 17,500. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.02 · Expires 2025-01-05 | Direct | 0 |
Reported balance
After 2020-04-01 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2020-04-01 · Exercise / conversion · Disposed 58,519 · Balance 0 F5: These options, representing the right to purchase a total of 180,000 shares, became exercisable in equal quarterly installments, contingent upon continued service to the Company, with the first vesting date on April 5, 2015, which was one quarter after the date on which the option was granted. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.20 · Expires 2028-02-07 | Direct | 95,035 |
Reported balance
After 2020-04-01 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2020-04-01 · Exercise / conversion · Disposed 3,090 · Balance 95,035 F6: These options, representing the right to purchase a total of 100,000 shares, became exercisable in equal quarterly installments, contingent upon continued service to the Company, with the first vesting date on May 7, 2018, which was one quarter after the date on which the option was granted. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.65 · Expires 2027-05-22 | Direct | 13,125 |
Reported balance
After 2020-04-01 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2020-04-01 · Exercise / conversion · Disposed 1,875 · Balance 13,125 F7: 6.25% of these options, representing the right to purchase a total of 30,000 shares, became exercisable immediately on May 22, 2017. An additional 6.25% became exercisable on August 8, 2017 and continue to vest in equal quarterly installments from August 8, 2017, contingent upon the continued service to the Company. F8: These transaction relate to the 30,000 stock options granted to Mr. Michel on May 22, 2017. The remaining beneficially owned stock option (right to buy) after both transactions is 7,500. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.75 · Expires 2027-02-08 | Direct | 17,500 |
Reported balance
After 2020-04-01 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2020-04-01 · Exercise / conversion · Disposed 7,673 · Balance 17,500 F3: These options, representing the right to purchase a total of 70,000 shares, became exercisable in equal quarterly installments, contingent upon continued service to the Company, with the first vesting date on May 8, 2017, which was one quarter after the date on which the option was granted. F4: These transactions relate to the 70,000 stock options granted to Mr. Michel on February 8, 2017. The remaining beneficially owned stock option (right to buy) after both transactions is 17,500. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.65 · Expires 2027-05-22 | Direct | 7,500 |
Reported balance
After 2020-04-01 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2020-04-01 · Exercise / conversion · Disposed 5,625 · Balance 7,500 F7: 6.25% of these options, representing the right to purchase a total of 30,000 shares, became exercisable immediately on May 22, 2017. An additional 6.25% became exercisable on August 8, 2017 and continue to vest in equal quarterly installments from August 8, 2017, contingent upon the continued service to the Company. F8: These transaction relate to the 30,000 stock options granted to Mr. Michel on May 22, 2017. The remaining beneficially owned stock option (right to buy) after both transactions is 7,500. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).
F2: These options, representing the right to purchase a total of 80,000 shares, became exercisable in equal quarterly installments, contingent upon continued service to the Company, with the first vesting date on May 9, 2016, which was one quarter after the date on which the option was granted.
F3: These options, representing the right to purchase a total of 70,000 shares, became exercisable in equal quarterly installments, contingent upon continued service to the Company, with the first vesting date on May 8, 2017, which was one quarter after the date on which the option was granted.
F4: These transactions relate to the 70,000 stock options granted to Mr. Michel on February 8, 2017. The remaining beneficially owned stock option (right to buy) after both transactions is 17,500.
F5: These options, representing the right to purchase a total of 180,000 shares, became exercisable in equal quarterly installments, contingent upon continued service to the Company, with the first vesting date on April 5, 2015, which was one quarter after the date on which the option was granted.
F6: These options, representing the right to purchase a total of 100,000 shares, became exercisable in equal quarterly installments, contingent upon continued service to the Company, with the first vesting date on May 7, 2018, which was one quarter after the date on which the option was granted.
F7: 6.25% of these options, representing the right to purchase a total of 30,000 shares, became exercisable immediately on May 22, 2017. An additional 6.25% became exercisable on August 8, 2017 and continue to vest in equal quarterly installments from August 8, 2017, contingent upon the continued service to the Company.
F8: These transaction relate to the 30,000 stock options granted to Mr. Michel on May 22, 2017. The remaining beneficially owned stock option (right to buy) after both transactions is 7,500.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 21, 2026 Filed May 26, 2026 22:00 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | GrantCommon Stock | 16,965 | $0.00 | $0.00 |
DisclosureSEC source: 0001235644-26-000008 · form4-05262026_060533.xml · nonDerivative · entry 1 MICHEL GERARD J · CIK 0001235644 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,509 F1 · shares: Represents restricted stock unit award granted under the Issuer's 2025 Equity Incentive Plan. Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 21:15 UTC | DELCATH SYSTEMS, INC. DCTH · Entity 5387 | PurchaseCommon Stock | 11,200 | $8.96 | $100,309.44 |
DisclosureSEC source: 0001235644-26-000007 · form4-03032026_040309.xml · nonDerivative · entry 1 MICHEL GERARD J · CIK 0001235644 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 342,034 Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 02:30 UTC | DELCATH SYSTEMS, INC. DCTH · Entity 5387 | GrantRestricted Stock Units · Derivative | 97,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001235644-26-000005 · form4-02182026_090201.xml · derivative · entry 2 MICHEL GERARD J · CIK 0001235644 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 97,500 Underlying: Common Stock · 97,500 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: Represents an RSU award, one-third of which shall vest on February 17, 2027 with the remaining two-thirds of the RSUs vesting in equal annual installments over the following two years. The vesting of the RSUs is subject to the Reporting Person's continuous service through each such vesting date. F3 · derivative.expiration_date: Represents an RSU award, one-third of which shall vest on February 17, 2027 with the remaining two-thirds of the RSUs vesting in equal annual installments over the following two years. The vesting of the RSUs is subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 02:30 UTC | DELCATH SYSTEMS, INC. DCTH · Entity 5387 | GrantStock Option (Right to Buy) · Derivative | 195,000 | $0.00 Strike: $9.40 | $0.00 |
DisclosureSEC source: 0001235644-26-000005 · form4-02182026_090201.xml · derivative · entry 1 MICHEL GERARD J · CIK 0001235644 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 195,000 Underlying: Common Stock · 195,000 shares Expires 2036-02-17 F1 · derivative.exercise_date: The option will vest and become exercisable at the rate of one-thirty-sixth (1/36th) per month with the first such vesting to occur on February 17, 2026 and monthly thereafter for so long as the reporting person remains an employee of Delcath Systems, Inc. (and subject to the terms and conditions of the Delcath Systems, Inc. 2020 Omnibus Equity Incentive Plan, as amended). Read SEC document |
| January 13, 2026 Filed Jan 15, 2026 01:30 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | GrantCommon Stock | 3,997 | $0.00 | $0.00 |
DisclosureSEC source: 0001235644-26-000002 · form4-01142026_080110.xml · nonDerivative · entry 1 MICHEL GERARD J · CIK 0001235644 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,544 F1 · shares: Represents restricted stock unit award granted under the Issuer's 2025 Equity Incentive Plan. Read SEC document |
| November 11, 2025 Filed Nov 13, 2025 16:53 UTC | DELCATH SYSTEMS, INC. DCTH · Entity 5387 | PurchaseCommon Stock | 11,500 | $8.53 | $98,049.00 |
DisclosureSEC source: 0001235644-25-000004 · form4-11132025_041124.xml · nonDerivative · entry 1 MICHEL GERARD J · CIK 0001235644 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 330,834 Read SEC document |
| March 26, 2025 Filed Mar 27, 2025 23:04 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | GrantCommon Stock | 12,547 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-009123 · form4-03272025_110352.xml · nonDerivative · entry 1 MICHEL GERARD J · CIK 0001235644 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,547 F1 · shares: Represents restricted stock unit award granted under the Issuer's 2025 Equity Incentive Plan. Read SEC document |
| February 07, 2025 Filed Feb 8, 2025 00:03 UTC | DELCATH SYSTEMS, INC. DCTH · Entity 5387 | GrantStock Option (Right to Buy) · Derivative | 390,000 | $0.00 Strike: $16.25 | $0.00 |
DisclosureSEC source: 0001415889-25-003402 · form4-02082025_120252.xml · derivative · entry 1 MICHEL GERARD J · CIK 0001235644 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 390,000 Underlying: Common Stock · 390,000 shares Expires 2035-02-07 F1 · derivative.exercise_date: The option will vest and become exercisable at the rate of one-thirty-sixth (1/36th) per month with the first such vesting to occur on February 7, 2025 and monthly thereafter for so long as the reporting person remains an employee of Delcath Systems, Inc. (and subject to the terms and conditions of the Delcath Systems, Inc. 2020 Omnibus Equity Incentive Plan, as amended). Read SEC document |
| October 22, 2024 Filed Oct 23, 2024 20:17 UTC | DELCATH SYSTEMS, INC. DCTH · Entity 5387 | Exercise / conversionTranche B Warrants to Purchase Common Stock · Derivative | 16,666 | $0.13 Strike: $6.00 | $2,083.25 |
DisclosureSEC source: 0001415889-24-025566 · form4-10232024_081038.xml · derivative · entry 2 MICHEL GERARD J · CIK 0001235644 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,666 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: The Tranche B Warrants were acquired in the issuer's private placement of common stock and warrants and issued as part of a unit with common stock and Tranche A Warrants. The per unit purchase price was $5.09, including a purchase price of $4.84 per share of common stock and $0.125 for each of the Tranche A and Tranche B Warrants. Each unit consisted of one share of common stock and an accompanying common stock warrant valued at 140% of the aggregate purchase price (the Tranche A Warrant) and an accompanying common stock warrant valued at 100% of the aggregate purchase price (the Tranche B Warrant). F1 · derivative.exercise_date: Immediately exercisable. F2 · derivative.expiration_date: The Tranche B Warrants expire the earlier of (i) twenty-one (21) days following the date of the Issuer's public announcement of record at least $10,000,000 in quarterly U.S. revenue from the commercialization of HEPZATO and (ii) March 31, 2026, provided, however, if the FDA Approval occurs on or before February 15, 2024 and the Tranche A Warrants have not been exercised in full on or before March 7, 2024, then the Tranche B Warrants shall automatically expire on March 8, 2024. The Issuer announced on October 17, 2024 that it had recorded at least $10,000,000 in quarterly U.S. revenue from the commercialization of HEPZATO and therefore such Tranche B Warrants expire on November 7, 2024. Read SEC document |
| October 22, 2024 Filed Oct 23, 2024 20:17 UTC | DELCATH SYSTEMS, INC. DCTH · Entity 5387 | Exercise / conversionCommon Stock | 16,666 | $6.00 | $99,996.00 |
DisclosureSEC source: 0001415889-24-025566 · form4-10232024_081038.xml · nonDerivative · entry 1 MICHEL GERARD J · CIK 0001235644 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 319,334 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 19, 2024 Filed Mar 19, 2024 21:01 UTC | DELCATH SYSTEMS, INC. DCTH · Entity 5387 | GrantCommon Stock | 40,323 | $3.72 | $150,001.56 |
DisclosureSEC source: 0001415889-24-008585 · form4-03192024_090329.xml · nonDerivative · entry 1 MICHEL GERARD J · CIK 0001235644 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 302,668 Read SEC document |
| February 12, 2024 Filed Feb 14, 2024 21:46 UTC | DELCATH SYSTEMS, INC. DCTH · Entity 5387 | GrantStock Option (Right to Buy) · Derivative | 301,500 | $0.00 Strike: $4.78 | $0.00 |
DisclosureSEC source: 0001415889-24-003762 · form4-02142024_090249.xml · derivative · entry 1 MICHEL GERARD J · CIK 0001235644 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 301,500 Underlying: Common Stock · 301,500 shares Expires 2034-02-12 F1 · derivative.exercise_date: The option will vest and become exercisable at the rate of one-thirty-sixth (1/36th) per month with the first such vesting to occur on February 12, 2024 and monthly thereafter for so long as the reporting person remains an employee of Delcath Systems, Inc. (and subject to the terms and conditions of the Delcath Systems, Inc. 2020 Omnibus Equity Incentive Plan, as amended). Read SEC document |
| December 08, 2023 Filed Dec 11, 2023 22:02 UTC | DELCATH SYSTEMS, INC. DCTH · Entity 5387 | PurchaseCommon Stock | 34,000 | $2.94 | $99,960.00 |
DisclosureSEC source: 0001209191-23-058085 · doc4.xml · nonDerivative · entry 1 MICHEL GERARD J · CIK 0001235644 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 262,345 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.88 to $2.98 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| August 18, 2023 Filed Aug 21, 2023 16:05 UTC | DELCATH SYSTEMS, INC. DCTH · Entity 5387 | OtherTranche A Warrants to Purchase Common Stock · Derivative | 31,110 | $0.13 Strike: $4.50 | $3,888.75 |
DisclosureSEC source: 0001209191-23-046672 · doc4.xml · derivative · entry 2 MICHEL GERARD J · CIK 0001235644 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 31,110 shares Expires not disclosed F3 · price: The common stock and Tranche A and Tranche B Warrants were acquired in the issuer's private placement of common stock and warrants, issued as part of a unit. The per unit purchase price was $5.09, including a purchase price of $4.84 per share of common stock and $0.125 for each of the Tranche A and Tranche B Warrants. Each unit consisted of one share of common stock and an accompanying common stock warrant valued at 140% of the aggregate purchase price (the Tranche A Warrant) and an accompanying common stock warrant valued at 100% of the aggregate purchase price (the Tranche B Warrant). F1 · derivative.exercise_date: The Tranche A Warrants are immediately exercisable. F2 · derivative.expiration_date: The Tranche A Warrants expire the earlier of (i) twenty-one (21) days following the date of the Issuer's public announcement of its receipt of written approval from the U.S. Food and Drug Administration of its New Drug Application for HEPZATO (the "FDA Approval") and (ii) March 31, 2026. Read SEC document |
| August 18, 2023 Filed Aug 21, 2023 16:05 UTC | DELCATH SYSTEMS, INC. DCTH · Entity 5387 | OtherCommon Stock | 31,110 | $4.50 | $139,995.00 |
DisclosureSEC source: 0001209191-23-046672 · doc4.xml · nonDerivative · entry 1 MICHEL GERARD J · CIK 0001235644 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 228,345 Read SEC document |
| June 12, 2023 Filed Jun 22, 2023 01:19 UTC | DELCATH SYSTEMS, INC. DCTH · Entity 5387 | GrantStock Option (Right to Buy) · Derivative | 168,887 | $0.00 Strike: $7.25 | $0.00 |
DisclosureSEC source: 0000899243-23-016197 · doc4.xml · derivative · entry 1 MICHEL GERARD J · CIK 0001235644 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 168,887 Underlying: Common Stock · 168,887 shares Expires 2033-06-12 F1 · derivative.exercise_date: The option will vest and become exercisable at the rate of one-thirty-sixth (1/36th) per month with the first such vesting to occur on July 12, 2023 and monthly thereafter for so long as the reporting person remains an employee of Delcath Systems, Inc. (and subject to the terms and conditions of the Delcath Systems, Inc. 2020 Omnibus Equity Incentive Plan, as amended). Read SEC document |
| March 29, 2023 Filed Mar 30, 2023 13:00 UTC | DELCATH SYSTEMS, INC. DCTH · Entity 5387 | PurchaseTranche B Warrants to Purchase Common Stock · Derivative | 16,666 | $0.13 Strike: $6.00 | $2,083.25 |
DisclosureSEC source: 0000899243-23-010009 · doc4.xml · derivative · entry 3 MICHEL GERARD J · CIK 0001235644 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,666 Underlying: Common Stock · 16,666 shares Expires not disclosed F1 · price: The common stock and Tranche A and Tranche B Warrants were acquired in the issuer's private placement of common stock and warrants, issued as part of a unit. The per unit purchase price was $5.09, including a purchase price of $4.84 per share of common stock and $0.125 for each of the Tranche A and Tranche B Warrants. Each unit consisted of one share of common stock and an accompanying common stock warrant valued at 140% of the aggregate purchase price (the Tranche A Warrant) and an accompanying common stock warrant valued at 100% of the aggregate purchase price (the Tranche B Warrant). F2 · derivative.exercise_date: The Tranche A Warrants and Tranche B Warrants are immediately exercisable. F4 · derivative.expiration_date: The Tranche B Warrants expire the earlier of (i) twenty-one (21) days following the date of the Issuer's public announcement of record at least $10,000,000 in quarterly U.S. revenue from the commercialization of HEPZATO and (ii) March 31, 2026, provided, however, if the FDA Approval occurs on or before February 15, 2024 and the Tranche A Warrants have not been exercised in full on or before March 7, 2024, then the Tranche B Warrants shall automatically expire on March 8, 2024. Read SEC document |
| March 29, 2023 Filed Mar 30, 2023 13:00 UTC | DELCATH SYSTEMS, INC. DCTH · Entity 5387 | PurchaseTranche A Warrants to Purchase Common Stock · Derivative | 31,110 | $0.13 Strike: $4.50 | $3,888.75 |
DisclosureSEC source: 0000899243-23-010009 · doc4.xml · derivative · entry 2 MICHEL GERARD J · CIK 0001235644 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,110 Underlying: Common Stock · 31,110 shares Expires not disclosed F1 · price: The common stock and Tranche A and Tranche B Warrants were acquired in the issuer's private placement of common stock and warrants, issued as part of a unit. The per unit purchase price was $5.09, including a purchase price of $4.84 per share of common stock and $0.125 for each of the Tranche A and Tranche B Warrants. Each unit consisted of one share of common stock and an accompanying common stock warrant valued at 140% of the aggregate purchase price (the Tranche A Warrant) and an accompanying common stock warrant valued at 100% of the aggregate purchase price (the Tranche B Warrant). F2 · derivative.exercise_date: The Tranche A Warrants and Tranche B Warrants are immediately exercisable. F3 · derivative.expiration_date: The Tranche A Warrants expire the earlier of (i) twenty-one (21) days following the date of the Issuer's public announcement of its receipt of written approval from the U.S. Food and Drug Administration of its New Drug Application for HEPZATO (the "FDA Approval") and (ii) March 31, 2026. Read SEC document |
| March 29, 2023 Filed Mar 30, 2023 13:00 UTC | DELCATH SYSTEMS, INC. DCTH · Entity 5387 | PurchaseCommon Stock | 19,646 | $4.84 | $95,086.64 |
DisclosureSEC source: 0000899243-23-010009 · doc4.xml · nonDerivative · entry 1 MICHEL GERARD J · CIK 0001235644 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 197,235 F1 · price: The common stock and Tranche A and Tranche B Warrants were acquired in the issuer's private placement of common stock and warrants, issued as part of a unit. The per unit purchase price was $5.09, including a purchase price of $4.84 per share of common stock and $0.125 for each of the Tranche A and Tranche B Warrants. Each unit consisted of one share of common stock and an accompanying common stock warrant valued at 140% of the aggregate purchase price (the Tranche A Warrant) and an accompanying common stock warrant valued at 100% of the aggregate purchase price (the Tranche B Warrant). Read SEC document |
| February 08, 2023 Filed Jan 26, 2024 21:21 UTC | DELCATH SYSTEMS, INC. DCTH · Entity 5387 | GrantStock Option (Right to Buy) · Derivative | 140,400 | $0.00 Strike: $4.67 | $0.00 |
DisclosureSEC source: 0001415889-24-001864 · form4-01262024_090156.xml · derivative · entry 1 MICHEL GERARD J · CIK 0001235644 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 140,400 Underlying: Common Stock · 140,400 shares Expires 2033-02-08 F1 · derivative.exercise_date: The option will vest and become exercisable at the rate of one-thirty-sixth (1/36th) per month with the first such vesting to occur on February 8, 2023 and monthly thereafter for so long as the reporting person remains an employee of Delcath Systems, Inc. (and subject to the terms and conditions ofthe Delcath Systems, Inc. 2020 Omnibus Equity Incentive Plan, as amended). Read SEC document |
| December 13, 2022 Filed Dec 14, 2022 20:33 UTC | DELCATH SYSTEMS, INC. DCTH · Entity 5387 | PurchaseCommon Stock | 51,725 | $2.90 | $150,002.50 |
DisclosureSEC source: 0000899243-22-038446 · doc4.xml · nonDerivative · entry 1 MICHEL GERARD J · CIK 0001235644 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 177,589 Read SEC document |
| July 20, 2022 Filed Jul 21, 2022 14:29 UTC | DELCATH SYSTEMS, INC. DCTH · Entity 5387 | PurchaseCommon Stock | 62,814 | $3.98 | $249,999.72 |
DisclosureSEC source: 0000899243-22-026440 · doc4.xml · nonDerivative · entry 1 MICHEL GERARD J · CIK 0001235644 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,864 Read SEC document |
| April 18, 2022 Filed Apr 19, 2022 01:23 UTC | DELCATH SYSTEMS, INC. DCTH · Entity 5387 | PurchaseCommon Stock | 1,800 | $6.37 | $11,466.00 |
DisclosureSEC source: 0000899243-22-015014 · doc4.xml · nonDerivative · entry 2 MICHEL GERARD J · CIK 0001235644 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,050 Read SEC document |
| April 18, 2022 Filed Apr 19, 2022 01:23 UTC | DELCATH SYSTEMS, INC. DCTH · Entity 5387 | PurchaseCommon Stock | 200 | $6.34 | $1,268.00 |
DisclosureSEC source: 0000899243-22-015014 · doc4.xml · nonDerivative · entry 1 MICHEL GERARD J · CIK 0001235644 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,250 Read SEC document |
| April 08, 2022 Filed Apr 8, 2022 22:25 UTC | DELCATH SYSTEMS, INC. DCTH · Entity 5387 | PurchaseCommon Stock | 1,000 | $6.55 | $6,546.00 |
DisclosureSEC source: 0000899243-22-014377 · doc4.xml · nonDerivative · entry 2 MICHEL GERARD J · CIK 0001235644 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,050 Read SEC document |
| April 08, 2022 Filed Apr 8, 2022 22:25 UTC | DELCATH SYSTEMS, INC. DCTH · Entity 5387 | PurchaseCommon Stock | 1,000 | $6.59 | $6,590.00 |
DisclosureSEC source: 0000899243-22-014377 · doc4.xml · nonDerivative · entry 1 MICHEL GERARD J · CIK 0001235644 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,050 Read SEC document |
| February 08, 2022 Filed Feb 16, 2022 23:51 UTC | DELCATH SYSTEMS, INC. DCTH · Entity 5387 | GrantEmployee Stock Option (right to buy) · Derivative | 116,137 | $0.00 Strike: $7.14 | $0.00 |
DisclosureSEC source: 0000899243-22-006662 · doc4.xml · derivative · entry 1 MICHEL GERARD J · CIK 0001235644 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,137 Underlying: Common Stock · 116,137 shares Expires 2032-02-08 F1 · derivative.exercise_date: The option shares will vest and become exercisable in equal monthly installments over the 36-month period beginning on the grant date (1/36th will vest on the first day of each month during said 36-month period, with the first vesting date being March 1, 2022, for so long as the reporting person remains an employee of Delcath Systems, Inc. (and subject to the terms and conditions of the Delcath Systems, Inc. 2020 Omnibus Equity Incentive Plan). Read SEC document |
| December 02, 2021 Filed Dec 6, 2021 23:06 UTC | DELCATH SYSTEMS, INC. DCTH · Entity 5387 | PurchaseCommon Stock | 23,200 | $8.61 | $199,752.00 |
DisclosureSEC source: 0000899243-21-046986 · doc4.xml · nonDerivative · entry 1 MICHEL GERARD J · CIK 0001235644 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,050 F1 · price: The price reported in Column 4 is a weighted average price rounded to the nearest hundredth. The shares were purchased in multiple transactions at prices ranging from $8.38 to $9.00, inclusive. The reporting person undertakes to provide to Delcath Systems, Inc., any securityholder of Delcath Systems, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the ranges set forth in this footnote. Read SEC document |
| August 05, 2021 Filed Aug 9, 2021 20:26 UTC | DELCATH SYSTEMS, INC. DCTH · Entity 5387 | GrantEmployee Stock Option (right to buy) · Derivative | 125,000 | $0.00 Strike: $10.16 | $0.00 |
DisclosureSEC source: 0000899243-21-032156 · doc4.xml · derivative · entry 1 MICHEL GERARD J · CIK 0001235644 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2031-08-05 F1 · derivative.exercise_date: The option immediately vested with respect to four-thirty-sixths (4/36ths) of the option shares and the remaining option shares will vest and become exercisable at the rate of one-thirty-sixth (1/36th) per month on the first day of each month for the next thirty-two months, starting on September 1, 2021, for so long as the reporting person remains an employee of Delcath Systems, Inc. (and subject to the terms and conditions of the Delcath Systems, Inc. 2020 Omnibus Equity Incentive Plan). Read SEC document |
| June 28, 2021 Filed Jun 29, 2021 17:46 UTC | DELCATH SYSTEMS, INC. DCTH · Entity 5387 | PurchaseCommon Stock | 6,250 | $11.93 | $74,562.50 |
DisclosureSEC source: 0000899243-21-026501 · doc4.xml · nonDerivative · entry 2 MICHEL GERARD J · CIK 0001235644 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,850 F1 · price: The price reported in Column 4 is a weighted average price rounded to the nearest hundredth. The shares purchased on June 25, 2021 were purchased in multiple transactions at prices ranging from $11.4915 to $11.24, inclusive. The shares purchased on June 28, 2021 were purchased in multiple transactions at prices ranging from $12.25 to $11.67, inclusive. The reporting person undertakes to provide to Delcath Systems, Inc., any securityholder of Delcath Systems, Inc., or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the ranges set forth in this footnote. Read SEC document |
| June 25, 2021 Filed Jun 29, 2021 17:46 UTC | DELCATH SYSTEMS, INC. DCTH · Entity 5387 | PurchaseCommon Stock | 6,600 | $11.35 | $74,910.00 |
DisclosureSEC source: 0000899243-21-026501 · doc4.xml · nonDerivative · entry 1 MICHEL GERARD J · CIK 0001235644 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,600 F1 · price: The price reported in Column 4 is a weighted average price rounded to the nearest hundredth. The shares purchased on June 25, 2021 were purchased in multiple transactions at prices ranging from $11.4915 to $11.24, inclusive. The shares purchased on June 28, 2021 were purchased in multiple transactions at prices ranging from $12.25 to $11.67, inclusive. The reporting person undertakes to provide to Delcath Systems, Inc., any securityholder of Delcath Systems, Inc., or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the ranges set forth in this footnote. Read SEC document |
| April 05, 2021 Filed Apr 5, 2021 16:34 UTC | DELCATH SYSTEMS, INC. DCTH · Entity 5387 | PurchaseCommon Stock | 15,500 | $12.88 | $199,640.00 |
DisclosureSEC source: 0000899243-21-014744 · doc4.xml · nonDerivative · entry 1 MICHEL GERARD J · CIK 0001235644 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.58 to $13.00, inclusive. The reporting person undertakes to provide to Delcath Systems, Inc., any securityholder of Delcath Systems, Inc., or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the ranges set forth in this footnote. Read SEC document |
| December 11, 2020 Filed Dec 14, 2020 19:00 UTC | DELCATH SYSTEMS, INC. DCTH · Entity 5387 | PurchaseCommon Stock | 7,500 | $13.25 | $99,375.00 |
DisclosureSEC source: 0000899243-20-033719 · doc4.xml · nonDerivative · entry 1 MICHEL GERARD J · CIK 0001235644 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 F1 · shares: The shares were purchased in a confidentially marketed public offering pursuant to an underwriting agreement. The offering closed on December 11, 2020. F1 · price: The shares were purchased in a confidentially marketed public offering pursuant to an underwriting agreement. The offering closed on December 11, 2020. Read SEC document |
| October 01, 2020 Filed Oct 5, 2020 23:29 UTC | DELCATH SYSTEMS, INC. DCTH · Entity 5387 | GrantEmployee Stock Option (right to buyer) · Derivative | 498,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-027378 · doc4.xml · derivative · entry 1 MICHEL GERARD J · CIK 0001235644 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 498,000 Underlying: Common Stock · 498,000 shares Expires 2020-10-01 F1 · derivative.exercise_price: The option was granted by Delcath Systems, Inc. (the "Issuer") as an inducement material to the reporting person's entering into employment with the Issuer in accordance with Nasdaq Listing Rule 5635(c)(4). The option will be exercisable at a price of (i) $11.67 per share as to the first 396,000 shares to vest, (ii) $17.505 as to the next 51,000 shares to vest and (iii) $23.34 as to the remaining 51,000 shares to vest. F2 · derivative.exercise_date: The option will vest ratably over thirty-six months, provided that the reporting person remains employed by the Issuer on each vesting date. Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 20:02 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionStock Option (right to buy) · Derivative | 5,625 | $0.00 Strike: $2.65 | $0.00 |
DisclosureSEC source: 0001593968-20-000976 · primary_01.xml · derivative · entry 14 MICHEL GERARD J · CIK 0001235644 · CFO and VP, Corp. Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 5,625 shares Expires 2027-05-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: 6.25% of these options, representing the right to purchase a total of 30,000 shares, became exercisable immediately on May 22, 2017. An additional 6.25% became exercisable on August 8, 2017 and continue to vest in equal quarterly installments from August 8, 2017, contingent upon the continued service to the Company. F8 · balance_after: These transaction relate to the 30,000 stock options granted to Mr. Michel on May 22, 2017. The remaining beneficially owned stock option (right to buy) after both transactions is 7,500. Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 20:02 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionStock Option (right to buy) · Derivative | 7,673 | $0.00 Strike: $2.75 | $0.00 |
DisclosureSEC source: 0001593968-20-000976 · primary_01.xml · derivative · entry 13 MICHEL GERARD J · CIK 0001235644 · CFO and VP, Corp. Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,500 Underlying: Common Stock · 7,673 shares Expires 2027-02-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: These options, representing the right to purchase a total of 70,000 shares, became exercisable in equal quarterly installments, contingent upon continued service to the Company, with the first vesting date on May 8, 2017, which was one quarter after the date on which the option was granted. F4 · balance_after: These transactions relate to the 70,000 stock options granted to Mr. Michel on February 8, 2017. The remaining beneficially owned stock option (right to buy) after both transactions is 17,500. Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 20:02 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionStock Option (right to buy) · Derivative | 1,875 | $0.00 Strike: $2.65 | $0.00 |
DisclosureSEC source: 0001593968-20-000976 · primary_01.xml · derivative · entry 12 MICHEL GERARD J · CIK 0001235644 · CFO and VP, Corp. Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,125 Underlying: Common Stock · 1,875 shares Expires 2027-05-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: 6.25% of these options, representing the right to purchase a total of 30,000 shares, became exercisable immediately on May 22, 2017. An additional 6.25% became exercisable on August 8, 2017 and continue to vest in equal quarterly installments from August 8, 2017, contingent upon the continued service to the Company. F8 · balance_after: These transaction relate to the 30,000 stock options granted to Mr. Michel on May 22, 2017. The remaining beneficially owned stock option (right to buy) after both transactions is 7,500. Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 20:02 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionStock Option (right to buy) · Derivative | 3,090 | $0.00 Strike: $7.20 | $0.00 |
DisclosureSEC source: 0001593968-20-000976 · primary_01.xml · derivative · entry 11 MICHEL GERARD J · CIK 0001235644 · CFO and VP, Corp. Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,035 Underlying: Common Stock · 3,090 shares Expires 2028-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: These options, representing the right to purchase a total of 100,000 shares, became exercisable in equal quarterly installments, contingent upon continued service to the Company, with the first vesting date on May 7, 2018, which was one quarter after the date on which the option was granted. Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 20:02 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionStock Option (right to buy) · Derivative | 58,519 | $0.00 Strike: $3.02 | $0.00 |
DisclosureSEC source: 0001593968-20-000976 · primary_01.xml · derivative · entry 10 MICHEL GERARD J · CIK 0001235644 · CFO and VP, Corp. Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 58,519 shares Expires 2025-01-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: These options, representing the right to purchase a total of 180,000 shares, became exercisable in equal quarterly installments, contingent upon continued service to the Company, with the first vesting date on April 5, 2015, which was one quarter after the date on which the option was granted. Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 20:02 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionStock Option (right to buy) · Derivative | 4,375 | $0.00 Strike: $2.75 | $0.00 |
DisclosureSEC source: 0001593968-20-000976 · primary_01.xml · derivative · entry 9 MICHEL GERARD J · CIK 0001235644 · CFO and VP, Corp. Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,173 Underlying: Common Stock · 4,375 shares Expires 2027-02-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: These options, representing the right to purchase a total of 70,000 shares, became exercisable in equal quarterly installments, contingent upon continued service to the Company, with the first vesting date on May 8, 2017, which was one quarter after the date on which the option was granted. F4 · balance_after: These transactions relate to the 70,000 stock options granted to Mr. Michel on February 8, 2017. The remaining beneficially owned stock option (right to buy) after both transactions is 17,500. Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 20:02 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $1.95 | $0.00 |
DisclosureSEC source: 0001593968-20-000976 · primary_01.xml · derivative · entry 8 MICHEL GERARD J · CIK 0001235644 · CFO and VP, Corp. Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2026-02-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: These options, representing the right to purchase a total of 80,000 shares, became exercisable in equal quarterly installments, contingent upon continued service to the Company, with the first vesting date on May 9, 2016, which was one quarter after the date on which the option was granted. Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 20:02 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionCommon Stock | 5,625 | $2.65 | $14,906.25 |
DisclosureSEC source: 0001593968-20-000976 · primary_01.xml · nonDerivative · entry 7 MICHEL GERARD J · CIK 0001235644 · CFO and VP, Corp. Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 253,865 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 20:02 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionCommon Stock | 7,673 | $2.75 | $21,100.75 |
DisclosureSEC source: 0001593968-20-000976 · primary_01.xml · nonDerivative · entry 6 MICHEL GERARD J · CIK 0001235644 · CFO and VP, Corp. Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 248,240 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 20:02 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionCommon Stock | 1,875 | $2.65 | $4,968.75 |
DisclosureSEC source: 0001593968-20-000976 · primary_01.xml · nonDerivative · entry 5 MICHEL GERARD J · CIK 0001235644 · CFO and VP, Corp. Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 240,567 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 20:02 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionCommon Stock | 3,090 | $7.20 | $22,248.00 |
DisclosureSEC source: 0001593968-20-000976 · primary_01.xml · nonDerivative · entry 4 MICHEL GERARD J · CIK 0001235644 · CFO and VP, Corp. Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 238,692 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 20:02 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionCommon Stock | 4,375 | $2.75 | $12,031.25 |
DisclosureSEC source: 0001593968-20-000976 · primary_01.xml · nonDerivative · entry 3 MICHEL GERARD J · CIK 0001235644 · CFO and VP, Corp. Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 235,602 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 20:02 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionCommon Stock | 58,519 | $3.02 | $176,727.38 |
DisclosureSEC source: 0001593968-20-000976 · primary_01.xml · nonDerivative · entry 2 MICHEL GERARD J · CIK 0001235644 · CFO and VP, Corp. Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 231,227 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 20:02 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionCommon Stock | 10,000 | $1.95 | $19,500.00 |
DisclosureSEC source: 0001593968-20-000976 · primary_01.xml · nonDerivative · entry 1 MICHEL GERARD J · CIK 0001235644 · CFO and VP, Corp. Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,708 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| February 11, 2020 Filed Feb 13, 2020 21:03 UTC | Vericel Corp VCEL · Entity 4481 | GrantRestricted Stock Unit · Derivative | 12,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001593968-20-000434 · primary_01.xml · derivative · entry 3 MICHEL GERARD J · CIK 0001235644 · CFO and VP, Corp. Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of Vericel Corporation. F3 · derivative.exercise_date: These RSUs vest in four annual installments with the initial vesting of RSUs granted to the Reporting Person on February 11, 2021. The remaining RSUs will vest in annual installments on February 11, 2022, February 11, 2023, and February 11, 2024, respectively. F4 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
| February 11, 2020 Filed Feb 13, 2020 21:03 UTC | Vericel Corp VCEL · Entity 4481 | GrantStock Option (right to buy) · Derivative | 5,555 | $0.00 Strike: $18.00 | $0.00 |
DisclosureSEC source: 0001593968-20-000434 · primary_01.xml · derivative · entry 2 MICHEL GERARD J · CIK 0001235644 · CFO and VP, Corp. Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,555 Underlying: Common Stock · 5,555 shares Expires 2030-02-11 F1 · derivative.exercise_date: These options shall begin vesting on February 11, 2020 and shall vest and become exercisable in equal quarterly installments over the course of the following four (4) year period. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.